
    
      The aim of this study is to identify and evaluate cardiotoxicity in patients with diagnosis
      of breast cancer, lymphoma or leukemia scheduled to receive anthracycline-based chemotherapy
      (Cohort A: prospective evaluation); and patients undergoing or having received within the
      last 5 years anthracycline-based chemotherapy (Cohort B: retrospective and prospective
      evaluations). Part A and B will be conducted in parallel. This study also has the objectif of
      identifying biomarkers of cardiotoxicity including inflammatory response proteins and clonal
      hematopoiesis.
    
  